세계의 의약품 개발용 차세대 시퀀싱(NGS) 시장

Highlights:

The global next-generation sequencing (NGS) market in drug development should reach $2.9 billion by 2028 from $1.3 billion in 2023 at a compound annual growth rate (CAGR) of 17.7% for the forecast period of 2023 to 2028.

North American NGS market in drug development is expected to grow from $539.8 million in 2023 to $1.2 billion in 2028 at a CAGR of 18.0% for the forecast period of 2023 to 2028.

Asia-Pacific NGS market in drug development is expected to grow from $311 million in 2023 to $743.6 million in 2028 at a CAGR of 19.0% for the forecast period of 2023 to 2028.

Report Scope:

The scope of this report includes NGS technologies, applications, industries, initiatives, patents and companies. The markets for NGS in drug development are given for 2020, 2021, 2022, 2023 and 2028.

This report reviews the NGS technologies and explains why NGS is important in drug development. It then discusses some of the significant research initiatives that impact NGS. The main market-driving forces are also discussed.

This report examines the markets by product type, end user and region. This report provides market data and forecasts for NGS by product type, including instruments, consumables and services for drug development.

Specific geographic markets are discussed, including North America, Europe, Asia-Pacific and the Rest of the World.

BCC Research summarizes the main industry acquisitions and strategic alliances from Jan. 2020, through Dec. 2022, including key alliance trends.

Report Includes:

• 52 data tables and 39 additional tables
• An overview of the global markets for next-generation sequencing on drug development
• Estimation of market size and analyses of global market trends, with data from 2020-2022, estimates for 2023, and projections of compound annual growth rates (CAGRs) through 2028
• Highlights of the market potential and characterization of next-generation sequencing on drug development market by product, service, end-user type, and region
• Examination of the key drivers and constraints that will shape the market for next-generation sequencing on drug development and discussion on the upcoming market opportunities and areas of focus to forecast the market into various segments and subsegments
• Coverage of recent advances, emerging technologies, and developments of the industry
• Evaluation of key industry acquisitions and strategic alliances and market share analysis of the leading suppliers of the industry
• Profiles of the key companies of the industry, including 10x Genomics, Bio-Rad Laboratories Inc., Oxford Nanopore Technologies, Qiagen and Takara Bio Inc.

Table of Contents

Chapter 1 Introduction

• Study Goals and Objectives
• Reasons for Doing This Study
• Scope of Report
• Research Methodology
• Information Sources
• Geographic Breakdown

Chapter 2 Summary and Highlights

• Market Outlook
• Market Summary

Chapter 3 Market Overview

• Introduction
• Technology Background
• Structure and Importance of DNA
• DNA Sequencing Technologies
• Whole Genome Sequencing
• Targeted Resequencing
• ChIP Sequencing
• RNA Sequencing
• Methylation Sequencing
• History of DNA Sequencing
• Sanger Sequencing
• Introduction to Next Generation Sequencing (NGS)
• Advantages of NGS
• Roche 454 Pyrosequencing
• Illumina NGS
• Thermo Fisher Scientific (Life Technologies) NGS
• Sequencing Instruments
• Benchtop Sequencers
• Informatics Technologies
• NGS in Drug Development
• NGS Service Providers

Chapter 4 Market Dynamics

• Market Drivers
• Increasing R&D Activities using NGS technologies
• Increase in Healthcare Expenditure
• Technological Advancements in Sequencing Platforms
• Shift Towards Precision Medicine
• Growing demand of NGS for Designing Individualized Medicine to Cancer Patients
• High Accuracy and Low Cost
• Market Restraints
• Limitations Associated with NGS Technology
• Other Clinical Sequencing Technology Challenges
• Market Opportunities
• Rising R&D in NGS creates lucrative Opportunities for Manufacturers

Chapter 5 NGS in Drug Development by Product Type

• Introduction
• Instruments
• Consumables
• Services

Chapter 6 NGS Market in Drug Development by End User

• Pharmaceutical and Biotechnology Companies
• Academic and Research Centers
• Other End Users

Chapter 7 NGS Market in Drug Development by Region

• Market Overview and Discussion
• North America
• Asia-Pacific
• Europe
• Rest of the World

Chapter 8 Sustainability of NGS in Drug Development: An ESG Perspective

• Introduction to ESG
• Sustainability of NGS in Drug Development: An ESG Perspective
• Key ESG Issues
• Consumer Attitudes Towards ESG
• Industry ESG Performance Analysis
• Case Study
• Environment
• Social
• Governance
• Concluding Remarks from BCC

Chapter 9 Emerging Technologies and Developments

• Overview
• Emerging Technologies in the Market
• Application of Artificial Intelligence (AI) in NGS
• Single-Molecule Real-Time Sequencing
• Nanopore Technology
• Microscopy-Based Sequencing

Chapter 10 Patent Analysis

• Introduction
• Patents on NGS by Region

Chapter 11 M&A and Funding Outlook

• M&A Analysis

Chapter 12 Competitive Landscape

• Global Company Ranking
• Global Company Ranking for NGS Instruments in Drug Development
• Global Company Ranking for NGS Consumables in Drug Development
• Global Company Ranking for NGS Services in Drug Development

Chapter 13 Company Profiles

• 10X GENOMICS
• AGILENT TECHNOLOGIES INC.
• BGI (BEIJING GENOMICS INSTITUTE)
• BIO-RAD LABORATORIES INC.
• CD GENOMICS
• ILLUMINA INC.
• INTEGRATED DNA TECHNOLOGIES INC.
• MICRONOMA
• NEW ENGLAND BIOLABS
• OXFORD NANOPORE TECHNOLOGIES
• PACIFIC BIOSCIENCES OF CALIFORNIA INC.
• PERKINELMER INC.
• PROMEGA CORP.
• PSOMAGEN INC.
• PRECISION FOR MEDICINE, FORMERLY APOCELL
• QIAGEN
• ROCHE HOLDING AG
• THERMO FISHER SCIENTIFIC INC.
• TAKARA BIO INC.
• TECAN GROUP LTD.

Chapter 14 Appendix: Acronyms